Benjamin Machinas Beneski - 01 Mar 2025 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role
SVP, Chief Technical Officer
Signature
/s/Earl Douglas, Attorney-in-Fact
Issuer symbol
ALLO
Transactions as of
01 Mar 2025
Net transactions value
$0
Form type
4
Filing time
05 Mar 2025, 16:11:13 UTC
Next filing
18 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALLO Common Stock Award $0 +31,755 +17% $0.000000 223,995 01 Mar 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALLO Stock Option (Right to buy) Award $0 +112,339 $0.000000 112,339 01 Mar 2025 Common Stock 112,339 $1.80 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the stock option shall vest on March 1, 2026, and the remaining shares shall vest in 36 equal monthly installments thereafter.